Table 3. Comparisons of KIR genes and their cognate HLA ligands between COVID-19 patients and the population group.
| Population group (400) | COVID-19 patients (396) | P value | OR (95% CI) | |
|---|---|---|---|---|
| n (%) | n (%) | |||
| KIR Ligands | ||||
| C1/C1 | 109 (0.273) | 102 (0.258) | 0.69 | 0.9 (0.7–1.3) |
| C2/C2 | 98 (0.245) | 111 (0.280) | 0.26 | 1.2 (0.9–1.7) |
| C1/C2 | 193 (0.483) | 183 (0.462) | 0.57 | 0.9 (0.7–1.2) |
| HLA Bw4 | 301 (0.753) | 306 (0.773) | 0.51 | 1.1 (0.8–1.6) |
| - Bw4 Ile80 | 269 (0.673) | 267 (0.674) | 1.00 | 1.0 (0.7–1.4) |
| -Bw4 Thr80 | 77 (0.193) | 93 (0.235) | 0.17 | 1.3 (0.9–1.8) |
| HLA Bw6 | 344 (0.860) | 336 (0.848) | 0.69 | 0.9 (0.6–1.4) |
| Activating KIR/HLA ligands | ||||
| 2DS1+/HLA-C2+ | 119 (0.298) | 139 (0.351) | 0.11 | 1.3 (0.9–1.7) |
| 2DS2+/HLA-C1+ | 177 (0.443) | 172 (0.434) | 0.83 | 1.0 (0.7–1.3) |
| 2DS4+/HLA-A*11+ or -C*04+ | 105 (0.263) | 101 (0.255) | 0.87 | 1.0 (0.7–1.3) |
| 3DS1+/HLA-Bw4+ | 118 (0.295) | 123 (0.311) | 0.64 | 1.1 (0.8–1.5) |
| Inhibitory KIR/HLA ligands | ||||
| 2DL1+/HLA C2+ | 278 (0.695) | 294 (0.742) | 0.16 | 1.3 (0.9–1.7) |
| 2DL2+/HLA C1+ | 178 (0.445) | 177 (0.447) | 1.00 | 1.0 (0.8–1.3) |
| 2DL3+/HLA C1+ | 259 (0.648) | 267 (0.674) | 0.45 | 1.1 (0.8–1.5) |
| 3DL1+/HLA Bw4+ | 282 (0.705) | 288 (0.727) | 0.53 | 1.1 (0.8–1.5) |
| 2DL2-3+/HLA C1+ | 137 (0.343) | 159 (0.402) | 0.09 | 1.3 (1.0–1.7) |
The diverse combinations of activating and inhibitory KIR genes with their cognate HLA ligands were analyzed and compared between the population group and patients.
Abbreviations: OR = odds ratio; CI = confidence interval; + = present.